Skip to main content

The public health significance of sleep disorders is substantial, accounting for hundreds of billions of
dollars each year in direct medical costs. Sleep disorders increase risk of neurocognitive and
cardiovascular morbidity and premature death. They also impair daily performance, increase pain sensitivity and decrease quality of life. Much of this disease burden could be averted with presently available treatment. Yet the majority of sleep disorders remain undiagnosed. This feasibility study will test the validity of the wrist-worn Jawbone Up[ and the ResMed S+ sleep monitors for estimating sleep stage and duration, and wake after sleep onset, by comparison with type 1 polysomnography (PSG), the current gold standard for sleep disorder diagnosis.

The objective is to evaluate the accuracy of the Jawbone Up and the ResMed S+ in estimating sleep
stages, total sleep time, and wake after sleep onset as measured against the gold standard of traditional in laboratory polysomnography. We hypothesize that the Jawbone Up and the ResMed S+ will provide sleep staging data comparable with those of PSG. These pilot data will serve as preliminary studies to support an evaluation of sleep and the response of sleep to therapy in a well-established NIH-sponsored study of chronic pain, as well as future studies.

Contact Person

Mary Ellen Wells

Website Address


Investigators and Key Personnel

Mary Ellen Wells (PI) Anne E Sanders, MS, PhD, MS (Co-PI) Bradley V. Vaughn, MD (Co-PI) Gregory Essick, DDS, PhD (Co-PI) Wanqing Zhang, PhD (Co-I) Shreya Nayak, BDS (Co-I)

Primary Funding Source